Posts by John

Bayer joins forces with CU Anschutz, UCHealth, and Children’s Hospital Colorado to accelerate drug development and expand access to critical clinical trials.

New Phase III trial data reveals that psilocybin therapy provides durable depression relief for six months, offering a breakthrough for treatment-resistance.

Increased US scrutiny of China-based clinical trials threatens to disrupt global drug development, forcing pharma firms to face rising costs and delays.

FibroBiologics achieves key milestone for CYWC628, a novel diabetic foot ulcer therapy, as it prepares for an upcoming Phase 1/2 clinical trial.

Despite $7 billion in funding, AI-driven drug discovery has yet to yield a single FDA-approved drug. Discover why the industry is shifting its strategy.

Anixa Biosciences has moved to the fifth cohort of its Phase 1 ovarian cancer vaccine trial, marking a key milestone in developing targeted immunotherapy.

Discover how agentic AI and real-world data are revolutionizing clinical trial design to accelerate drug development and enhance patient safety protocols.

Explore the latest trends in U.S. healthcare spending, the impact of medical innovation, and the shift toward value-based care in this expert-led analysis.

Smaller biotech firms are entering the weight-loss market with oral pills, challenging industry giants as they push for easier, scalable obesity treatment.

TG Therapeutics has launched a Phase 2 trial for BRIUMVI to treat resistant schizophrenia, exploring the role of B-cell depletion in psychiatric care.